373 related articles for article (PubMed ID: 34146170)
21. Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias.
Rached F; Santos RD
Curr Cardiol Rep; 2021 Jun; 23(7):83. PubMed ID: 34081216
[TBL] [Abstract][Full Text] [Related]
22. [Primary disorders of lipid metabolism: their place in current dyslipidemia guidelines and treatment innovations].
Klose G; Gouni-Berthold I; März W
Inn Med (Heidelb); 2023 Sep; 64(9):895-906. PubMed ID: 37280381
[TBL] [Abstract][Full Text] [Related]
23. New Biological Therapies for Low-Density Lipoprotein Cholesterol.
Gill PK; Hegele RA
Can J Cardiol; 2023 Dec; 39(12):1913-1930. PubMed ID: 37562541
[TBL] [Abstract][Full Text] [Related]
24. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
[TBL] [Abstract][Full Text] [Related]
25. MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment.
Burnett JR; Hooper AJ
Expert Opin Investig Drugs; 2023; 32(10):873-878. PubMed ID: 37815341
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
[TBL] [Abstract][Full Text] [Related]
27. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
28. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
Sinning D; Landmesser U
Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
[TBL] [Abstract][Full Text] [Related]
29. Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering.
Soffer D; Stoekenbroek R; Plakogiannis R
J Clin Lipidol; 2022; 16(5):574-582. PubMed ID: 35909047
[TBL] [Abstract][Full Text] [Related]
30. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
[TBL] [Abstract][Full Text] [Related]
31. Inclisiran in dyslipidemia.
Kosmas CE; Muñoz Estrella A; Sourlas A; Pantou D
Drugs Today (Barc); 2021 May; 57(5):311-319. PubMed ID: 34061126
[TBL] [Abstract][Full Text] [Related]
32. Dyslipidemia management update.
Chang Y; Robidoux J
Curr Opin Pharmacol; 2017 Apr; 33():47-55. PubMed ID: 28527325
[TBL] [Abstract][Full Text] [Related]
33. Updates in Small Interfering RNA for the Treatment of Dyslipidemias.
Carugo S; Sirtori CR; Gelpi G; Corsini A; Tokgozoglu L; Ruscica M
Curr Atheroscler Rep; 2023 Nov; 25(11):805-817. PubMed ID: 37792132
[TBL] [Abstract][Full Text] [Related]
34. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
35. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
[TBL] [Abstract][Full Text] [Related]
36. RNA Silencing in the Management of Dyslipidemias.
Henney NC; Banach M; Penson PE
Curr Atheroscler Rep; 2021 Sep; 23(11):69. PubMed ID: 34468873
[TBL] [Abstract][Full Text] [Related]
37. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
Viney NJ; Yeang C; Yang X; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075
[TBL] [Abstract][Full Text] [Related]
38. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia.
Banerjee Y; Pantea Stoian A; Cicero AFG; Fogacci F; Nikolic D; Sachinidis A; Rizvi AA; Janez A; Rizzo M
Expert Opin Drug Saf; 2022 Jan; 21(1):9-20. PubMed ID: 34596005
[TBL] [Abstract][Full Text] [Related]
39. Antisense oligonucleotides for the treatment of dyslipidemia.
Gouni-Berthold I; Berthold HK
Curr Pharm Des; 2011; 17(9):950-60. PubMed ID: 21418033
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
